New Guideline Revolutionizes Restless Legs Syndrome Treatment

**The American Academy of Sleep Medicine (AASM) has released updated guidelines for the treatment of Restless Legs Syndrome (RLS),** reflecting a significant shift in treatment protocols based on recent scientific evidence. RLS is characterized by an irresistible urge to move the legs, often leading to sleep disturbances and discomfort. **A key change in the guideline is the emphasis on evaluating iron levels** in all RLS patients, with a strong recommendation for intravenous ferric carboxymaltose and other iron supplements depending on iron indices. The guideline moves away from previously recommended treatments like pramipexole and ropinirole, as long-term usage can exacerbate symptoms—a phenomenon known as augmentation. Conversely, it endorses alpha-2-delta ligand calcium channel blockers like gabapentin enacarbil and pregabalin, as they do not carry the same risks. **Innovative treatments under conditional recommendations include bilateral high-frequency peroneal nerve stimulation** and low-dose opioids, while also recommending lifestyle adjustments to reduce exacerbating factors. The guideline was developed by a task force that reviewed literature systematically and applied the GRADE process, indicating a rigorous assessment of evidence and patient-centered care focus.